Final dosimetry results of IDEC-Y2B8 phase I II 90yttrium radioimmunothenapy trial in non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Wiseman, GA
White, CA
Witzig, TA
Stabin, MG
Spies, S
Silverman, DH
Raubitschek, A
Gordon, L
Emmanouilides, C
Janakiraman, N
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Idec Pharmaceut Corp, San Diego, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[6] Henry Ford Hosp, Detroit, MI 48202 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 1999年 / 40卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
260
引用
收藏
页码：64P / 64P
页数：1
相关论文
共 50 条
  • [41] Phase II multicenter trial of pentostatin and rituximal in patients with previously treated and untreated non-Hodgkin's lymphoma (NHL)
    Yunus, F
    George, S
    Smith, J
    Geils, G
    Geils, G
    BLOOD, 2003, 102 (11) : 642A - 643A
  • [42] Phase I/II study of fractionated radioimmunotherapy (RIT) in relapsed low grade non-Hodgkin's lymphoma (NHL).
    Bayne, M
    Zivanovic, M
    Du, Y
    Tutt, A
    Mead, G
    Johnson, P
    Lewington, V
    Illidge, I
    BRITISH JOURNAL OF CANCER, 2004, 91 : S8 - S8
  • [43] Phase I/II study of fractionated radioimmunotherapy (RIT) in relapsed low grade Non-Hodgkin's Lymphoma (NHL).
    Illidge, TM
    Bayne, MC
    Zivanovic, M
    Du, Y
    Lewington, V
    Peter, JW
    BLOOD, 2004, 104 (11) : 41A - 41A
  • [44] Phase I trial of combination therapy with 90Y ibritumomab tiuxetan (Zevalin) and gemicitabine in patients with non-hodgkin's lymphoma
    Borghaei, Hossein
    Smith, MitchellR.
    Millenson, Michael
    Thibodeau, Linda
    Kamiensky, Nicole
    Schilder, Russell J.
    BLOOD, 2007, 110 (11) : 192B - 193B
  • [45] Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): Phase I/II trial results.
    Leonard, JP
    Coleman, M
    Schuster, MW
    Chadburn, A
    Ely, S
    Yagan, N
    Sharkey, RM
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 1999, 94 (10) : 92A - 93A
  • [46] Final results of a phase I radioimmunotherapy trial using 186Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma
    Postema, EJ
    Raemaekers, JMM
    Oyen, WJG
    Boerman, OC
    Mandigers, CMPW
    Goldenberg, DM
    van Dongen, GAMS
    Corstens, FHM
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3995S - 4002S
  • [47] Phase II study of oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma: Final results.
    Oki, Y
    McLauhlin, P
    Pro, B
    Hagemeister, FH
    Bleyer, A
    Loyer, E
    Younes, A
    BLOOD, 2004, 104 (11) : 684A - 684A
  • [48] Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in the treatment of non-Hodgkin's lymphoma (NHL):: Incorporation into autologous stem cell transplantation (ASCT) regimens
    Nademanee, A
    Krishnan, A
    Fung, H
    Raubitschek, A
    Forman, S
    Molina, A
    ANNALS OF ONCOLOGY, 2005, 16 : 100 - 100
  • [49] Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL).
    Khouri, Issa F.
    Saliba, Rima M.
    Hosing, Chitra
    Valverde, Rosamar
    Erwin, William D.
    Fayad, Luis
    Maadani, Farzaneh
    Korbling, Martin J.
    Okoroji, Grace-Julia
    Stachowiak, Anne M.
    Samuels, Barry I.
    Anderlini, Paolo
    Couriel, Daniel R.
    de Lima, Marcos
    Giralt, Sergio
    Popat, Uday
    Kebriaei, Partow
    Ueno, Naoto T.
    Qazilbash, Muzaffar H.
    McLaughlin, Peter W.
    Hagemeister, Fredrick B.
    Younes, Anas
    Podoloff, Donald A.
    Champlin, Richard E.
    BLOOD, 2006, 108 (11) : 98A - 98A
  • [50] Interim results of a phase I/II radioimmunotherapy trial in relapsed/refractory non-Hodgkin's lymphoma (NHL) patients given 90Y-labeled anti-CD22 humanized monoclonal antibody, epratuzumab.
    Hajjar, G
    Sharkey, RM
    Burton, J
    Schuster, S
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, EA
    Leonard, J
    Coleman, M
    Plutchock, J
    Brenner, AI
    Goldenberg, DM
    BLOOD, 2001, 98 (11) : 611A - 611A
12345